TIL
Instil Bio, Inc. [TIL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TIL Stock Summary
Top 10 Correlated ETFs
TIL
Top 10 Correlated Stocks
TIL
In the News
TIL Financial details
Company Rating
-
Market Cap
70.86M
Income
-155.35M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-5.1
Forward P/E
-
PEG
1.66
P/S
-
P/B
4.28
P/C
-
P/FCF
-0.36
Quick Ratio
13.62
Current Ratio
14.53
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-23.89
EPS next Y
-
EPS next Q
-
EPS this Y
-30.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-80.81%
-
-
-
-
SMA20
-5.26%
SMA50
-14.29%
SMA100
-40%
Inst Own
-
Inst Trans
-
ROA
-58%
ROE
-65%
ROC
-0.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.08-14.0
52W High
+24.21%
52W Low
+189.83%
RSI
45
Rel Volume
2.36
Avg Volume
27.45K
Volume
64.7K
Perf Week
-5.28%
Perf Month
-27.57%
Perf Quarter
-55.02%
Perf Half Y
-73.5%
-
-
-
-
Beta
1.252
-
-
Volatility
0.68%, 1.35%
Prev Close
0.17%
Price
17.39
Change
0.33%
Company Profile
- Volume Average 27.45K
- Market Capitalization 70.86M
- Employee 49
- CEO Mr. Bronson Crouch
- Headquarters Dallas,TX,US
- IPO Date 2021-03-19
-
Website
https://instilbio.com 
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
